What a difference a year can make when it comes to infectious diseases and medical breakthroughs. Last year, the Ebola virus was an international public health crisis that claimed hundreds of lives every week in Guinea, Sierra Leone and Liberia at its height.
Entire economies in West Africa were at risk as other countries threatened flight and travel restrictions on nations where the outbreak was concentrated. The international community responded to the Ebola crisis by sending medical personnel into infected areas and building quarantine tents to shore up overwhelmed African health care systems. The spread of the virus began to slow, but it didn’t go away even as once-infected countries declared themselves Ebola free.
What was needed was a vaccine to stop the epidemic in its tracks. Last year an estimated 11,000 people died and 28,000 came down with the virus in the three most-affected countries.
The World Health Organization announced on July 31 that it has deployed a “highly effective” vaccine against Ebola in test trials. The WHO claims that tests of the single-dose VSV-EBOV vaccine that began in March in Guinea have been 100 percent effective for the 4,000 close contacts of 100 Ebola patients.
Because it has been so successful, the vaccinations will soon be extended to all people who come into contact with the infected, including health care workers, relatives, neighbors and friends. Though it will take weeks for another supply of the drugs to be made, it is a relief to know that stopping Ebola outbreaks may soon be routine.
The Public Health Agency of Canada and the pharmaceutical company Merck should be commended for developing the VSV-EBOV vaccine with input from doctors throughout the international community. More testing is needed to find out how long the vaccine will last and whether it has to be renewed annually, but for now it appears Ebola may have met its match.


Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.